logo

For the Inventor, By the Inventor

King of Prussia, PA, United States of America

Francis Xavier Muller

This inventor holds 8 USPTO granted patents and 12 published patent applications. Top assignees: Glaxosmithkline LLC, Glaxo Group Limited. Active years: 2011-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Francis Xavier Muller. Retrieved from https://idiyas.com/inventor/francis-xavier-muller

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 8 

% Patents Active = 100.0

Average Co-Inventor Count = 2.3

ph-index = 3

Forward Citations = 22(Granted Patents)


Company Filing History:

goldMedal6 out of 358 
 
Glaxosmithkline LLC
 patents
silverMedal2 out of 1,170 
 
Glaxo Group Limited
 patents

Years Active: 2011-2014

Loading Chart...
8 patents (USPTO):Explore Patents
1. 8828430 - 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (2014-09-09),
2. 8207191 - Process, salts, composition and use (2012-06-26),
3. 8071129 - 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (2011-12-06),
4. 8062665 - 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (2011-11-22),
5. 8052995 - 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (2011-11-08),
6. 8052994 - 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (2011-11-08),
7. 8052993 - 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (2011-11-08),
8. 7875630 - Process salts compositions and use (2011-01-25),

Title: The Innovative Contributions of Francis Xavier Muller

Introduction

Francis Xavier Muller, based in King of Prussia, Pennsylvania, is a distinguished inventor with an impressive portfolio of eight patents. His work primarily focuses on pharmaceutical compositions and processes that have potential applications in medical therapy. Muller's innovative mind has led to significant advancements in the field of medicinal chemistry.

Latest Patents

Among Muller's latest patents is a novel pharmaceutical composition involving 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine), commonly referred to as eltrombopag olamine. This composition aims to provide new therapeutic options. Another significant invention from Muller includes a novel process for preparing pleuromutilin derivatives, focusing on compounds like mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate. This work is particularly impactful in the domain of antibacterial therapy.

Career Highlights

Muller has made substantial contributions to the pharmaceutical industry, particularly during his tenure at notable companies such as GlaxoSmithKline LLC and Glaxo Group Limited. His experience in these leading organizations has shaped his understanding of the complexities involved in drug development and innovation.

Collaborations

Throughout his career, Muller has collaborated with esteemed professionals, including Shivakumar G Kapsi and Michael Anthony Forth. These partnerships have likely facilitated knowledge exchange and fostered a creative environment, leading to the development of groundbreaking inventions.

Conclusion

Francis Xavier Muller stands out as a prominent figure in the arena of pharmaceutical inventions, with his eight patents highlighting his dedication to medical science. His contributions reflect a commitment to improving health outcomes through innovative solutions, leaving a significant mark on the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…